257 related articles for article (PubMed ID: 33915015)
21. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
Liu PCC; Koblish H; Wu L; Bowman K; Diamond S; DiMatteo D; Zhang Y; Hansbury M; Rupar M; Wen X; Collier P; Feldman P; Klabe R; Burke KA; Soloviev M; Gardiner C; He X; Volgina A; Covington M; Ruggeri B; Wynn R; Burn TC; Scherle P; Yeleswaram S; Yao W; Huber R; Hollis G
PLoS One; 2020; 15(4):e0231877. PubMed ID: 32315352
[TBL] [Abstract][Full Text] [Related]
22. Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression.
Mori M; Mori T; Yamamoto A; Takagi S; Ueda M
Hum Cell; 2019 Jul; 32(3):367-378. PubMed ID: 30963412
[TBL] [Abstract][Full Text] [Related]
23. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.
Jo JC; Choi EK; Shin JS; Moon JH; Hong SW; Lee HR; Kim SM; Jung SA; Lee DH; Jung SH; Lee SH; Kim JE; Kim KP; Hong YS; Suh YA; Jang SJ; Choi EK; Lee JS; Jin DH; Kim TW
Mol Cancer Ther; 2015 Nov; 14(11):2613-22. PubMed ID: 26351320
[TBL] [Abstract][Full Text] [Related]
24. Endothelial fibroblast growth factor receptor signaling is required for vascular remodeling following cardiac ischemia-reperfusion injury.
House SL; Castro AM; Lupu TS; Weinheimer C; Smith C; Kovacs A; Ornitz DM
Am J Physiol Heart Circ Physiol; 2016 Mar; 310(5):H559-71. PubMed ID: 26747503
[TBL] [Abstract][Full Text] [Related]
25. Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors.
Li C; Dai Y; Kong X; Wang B; Peng X; Wu H; Shen Y; Yang Y; Ji Y; Wang D; Li S; Li X; Shi Y; Geng M; Zheng M; Ai J; Liu H
J Med Chem; 2023 Mar; 66(5):3226-3249. PubMed ID: 36802596
[TBL] [Abstract][Full Text] [Related]
26. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma.
Tsimafeyeu I; Demidov L; Stepanova E; Wynn N; Ta H
Scand J Urol Nephrol; 2011 Apr; 45(3):190-5. PubMed ID: 21329481
[TBL] [Abstract][Full Text] [Related]
28. Localisation and differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal and atherosclerotic human arteries.
Hughes SE
Cardiovasc Res; 1996 Sep; 32(3):557-69. PubMed ID: 8881516
[TBL] [Abstract][Full Text] [Related]
29. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
30. Targeting Fibroblast Growth Factor Receptor (FGFR) with BGJ398 in a Gastric Cancer Model.
Schmidt K; Moser C; Hellerbrand C; Zieker D; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
Anticancer Res; 2015 Dec; 35(12):6655-65. PubMed ID: 26637881
[TBL] [Abstract][Full Text] [Related]
31. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.
Datta J; Damodaran S; Parks H; Ocrainiciuc C; Miya J; Yu L; Gardner EP; Samorodnitsky E; Wing MR; Bhatt D; Hays J; Reeser JW; Roychowdhury S
Mol Cancer Ther; 2017 Apr; 16(4):614-624. PubMed ID: 28255027
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
[TBL] [Abstract][Full Text] [Related]
33. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer.
Saridogan T; Akcakanat A; Zhao M; Evans KW; Yuca E; Scott S; Kirby BP; Zheng X; Ha MJ; Chen H; Ng PKS; DiPeri TP; Mills GB; Rodon Ahnert J; Damodaran S; Meric-Bernstam F
Sci Rep; 2023 Nov; 13(1):20223. PubMed ID: 37980453
[TBL] [Abstract][Full Text] [Related]
35. A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity.
Kong Y; Zhao X; Wang Z; Yuan S; Chen S; Lou S; Ma S; Li Y; Wang X; Ge Y; Li G; Yang H; Zhao M; Li D; Zhang H; Tan W; Wang J
Mol Cancer Ther; 2024 Jun; ():OF1-OF11. PubMed ID: 38853423
[TBL] [Abstract][Full Text] [Related]
36. Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer.
Krook MA; Barker H; Chen HZ; Reeser JW; Wing MR; Martin D; Smith AM; Dao T; Bonneville R; Samorodnitsky E; Miya J; Freud AG; Monk JP; Clinton SK; Roychowdhury S
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):624-632. PubMed ID: 31043681
[TBL] [Abstract][Full Text] [Related]
37. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Abou-Alfa GK; Sahai V; Hollebecque A; Vaccaro G; Melisi D; Al-Rajabi R; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Ji T; Lihou CF; Zhen H; Féliz L; Vogel A
Lancet Oncol; 2020 May; 21(5):671-684. PubMed ID: 32203698
[TBL] [Abstract][Full Text] [Related]
38. Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer.
Packer LM; Stehbens SJ; Bonazzi VF; Gunter JH; Ju RJ; Ward M; Gartside MG; Byron SA; Pollock PM
Mol Oncol; 2019 Apr; 13(4):738-756. PubMed ID: 30537101
[TBL] [Abstract][Full Text] [Related]
39. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
40. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
